Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JORGE A GARCIA ZUAZAGA

Allopathic & Osteopathic Physicians Dermatology MOHS-Micrographic Surgery

NPI
1407979529
CMS profile
830298
Location
CONCORD TOWNSHIP, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$84,667.07

52 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 52 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JORGE A GARCIA ZUAZAGA

NPI 1407979529 · CMS profile ID 830298

Allopathic & Osteopathic Physicians / Dermatology / MOHS-Micrographic Surgery

CONCORD TOWNSHIP, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 52 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1407979529?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JORGE A GARCIA ZUAZAGA, NPI 1407979529, CMS profile ID 830298. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 52 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1407979529?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JORGE A GARCIA ZUAZAGA, NPI 1407979529, CMS profile ID 830298. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 52 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1407979529?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JORGE A GARCIA ZUAZAGA, NPI 1407979529, CMS profile ID 830298, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 52 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1407979529?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

52 matching records · $84,667.07 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 52 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 52.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
LEO Pharma Inc. $24.2612/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053472505 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $18.8412/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051613159 CMS
Amgen Inc. $13.9612/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020607321 CMS
E.R. Squibb & Sons, L.L.C. $20.0012/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016017329 CMS
ABBVIE INC. $617.0012/05/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997317463 CMS
Regeneron Healthcare Solutions, Inc. $22.1612/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999181501 CMS
Amgen Inc. $20.0011/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020607319 CMS
LEO Pharma Inc. $19.3211/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053472499 CMS
ABBVIE INC. $106.4011/09/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997317461 CMS
Lilly USA, LLC $20.5410/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031639745 CMS
GENZYME CORPORATION $17.7510/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049910675 CMS
ABBVIE INC. $15.2710/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997317459 CMS
Lilly USA, LLC $19.3610/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031612855 CMS
Lilly USA, LLC $16.1410/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031684485 CMS
ABBVIE INC. $14,206.6910/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997317457 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $24.8310/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051613157 CMS
ABBVIE INC. $16.7310/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997317455 CMS
ABBVIE INC. $282.5010/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997317453 CMS
GENZYME CORPORATION $20.0010/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049910667 CMS
E.R. Squibb & Sons, L.L.C. $15.0509/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016017257 CMS
Medimetriks Pharmaceuticals, Inc. $16.6709/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987616463 CMS
GENZYME CORPORATION $18.8909/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049910637 CMS
ABBVIE INC. $20.1609/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997317449 CMS
ABBVIE INC. $219.5009/12/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997317451 CMS
MAYNE PHARMA COMMERCIAL LLC $16.4309/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060915859 CMS
Lilly USA, LLC $17.0008/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031568653 CMS
ABBVIE INC. $14.8008/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997317447 CMS
Incyte Corporation $20.2107/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044728399 CMS
ABBVIE INC. $16,267.4907/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997317445 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.8407/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996559771 CMS
ABBVIE INC. $474.2007/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997317443 CMS
Medimetriks Pharmaceuticals, Inc. $21.8207/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987616465 CMS
ABBVIE INC. $14.2006/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997317441 CMS
Ethicon Inc. $505.0006/14/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 990874019 CMS
Incyte Corporation $23.9606/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044728363 CMS
ABBVIE INC. $249.6006/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997317439 CMS
Amgen Inc. $22.2205/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020607317 CMS
Incyte Corporation $40.3305/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044728289 CMS
Lilly USA, LLC $17.6705/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031612867 CMS
Incyte Corporation $20.0705/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044728247 CMS
Janssen Biotech, Inc. $99.9905/09/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988400963 CMS
Lilly USA, LLC $20.4004/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031645287 CMS
ABBVIE INC. $16,278.9704/17/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997317437 CMS
MAYNE PHARMA COMMERCIAL LLC $8.2304/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060915857 CMS
ABBVIE INC. $427.5004/07/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997317435 CMS
ABBVIE INC. $161.2003/10/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997317433 CMS
Lilly USA, LLC $16.9902/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031612861 CMS
Sun Pharmaceutical Industries Inc. $14.0302/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053877367 CMS
Lilly USA, LLC $20.0202/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031645283 CMS
ABBVIE INC. $34,039.0602/09/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997317431 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,268.57 21
PY2020 $1,238.59 7
PY2021 $12,408.53 45
PY2022 $24,381.63 42
PY2023 $84,667.07 52
PY2024 $16,980.08 79
PY2025 $2,421.43 52

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,893,327.58 407
PY2024 Principal investigator $2,667,688.93 422
PY2023 Recipient $18,196.50 3
PY2023 Principal investigator $882,864.23 139
PY2022 Principal investigator $164,380.88 32
PY2021 Recipient $18,912.00 5
PY2021 Principal investigator $12,300.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

142 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $1,935.00 12/27/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1040811391
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $44,383.90 12/14/2023 Non-covered Recipient Entity
Apex Clinical Research
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1061177838
Principal investigator 1 Janssen Research & Development, LLC $7,504.00 12/06/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 986127347
Principal investigator 1 Janssen Research & Development, LLC $350.00 12/06/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 986127349
Principal investigator 1 Janssen Research & Development, LLC $824.00 12/06/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 986127351
Principal investigator 1 Dermavant Sciences, Inc. $1,205.06 12/02/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993575699
Recipient Biocon Biologics Inc $1,016.50 11/29/2023 Covered Recipient Physician STELLAR-2 No dispute reported 06/30/2026 1038393347
Principal investigator 1 Janssen Research & Development, LLC $3,256.20 11/17/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 986127345
Principal investigator 1 Janssen Research & Development, LLC $3,256.20 11/17/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 986127359
Principal investigator 1 Janssen Research & Development, LLC $4,247.80 11/17/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 986127361
Principal investigator 1 Janssen Research & Development, LLC $4,247.80 11/17/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 986127363
Principal investigator 1 Janssen Research & Development, LLC $5,480.60 11/17/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 986127365
Principal investigator 1 Janssen Research & Development, LLC $5,480.60 11/17/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 986127367
Recipient Biocon Biologics Inc $3,200.00 11/16/2023 Covered Recipient Physician STELLAR-2 No dispute reported 06/30/2026 1038393353
Principal investigator 1 Incyte Corporation $5,138.00 11/16/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo No dispute reported 06/30/2026 1040811379
Principal investigator 1 Janssen Research & Development, LLC $5,275.00 11/16/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 986127343
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,910.00 11/15/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period No dispute reported 06/30/2026 1039783713
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 11/15/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period No dispute reported 06/30/2026 1039783719
Principal investigator 1 ABBVIE INC. $1,755.40 11/07/2023 Non-covered Recipient Entity
CABAN HEALTH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 998406291
Principal investigator 1 Incyte Corporation $1,465.89 11/02/2023 Non-covered Recipient Entity
APEX DERMATOLOGY
A Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus No dispute reported 06/30/2026 1040938387
Principal investigator 1 Dermavant Sciences, Inc. $1,611.14 11/01/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993568795
Principal investigator 1 Incyte Corporation $7,699.64 11/01/2023 Non-covered Recipient Entity
APEX DERMATOLOGY
A Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus No dispute reported 06/30/2026 1040938373
Principal investigator 1 Janssen Research & Development, LLC $6,165.00 10/28/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 986127341
Principal investigator 1 Janssen Research & Development, LLC $16,762.00 10/25/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 986127353
Principal investigator 1 Janssen Research & Development, LLC $1,800.00 10/25/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 986127355
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 10/25/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3017 No dispute reported 06/30/2026 986127357
Principal investigator 1 Eli Lilly and Company $4,529.20 10/20/2023 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS OF MARYLAND PA
PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED SINGLE-ARM PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB No dispute reported 06/30/2026 1038072725
Principal investigator 1 Incyte Corporation $4,414.00 10/19/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo No dispute reported 06/30/2026 1040811365
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,806.32 10/12/2023 Non-covered Recipient Entity
Delricht Research
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1027486039
Principal investigator 1 Dermavant Sciences, Inc. $1,205.06 10/11/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993567601
Principal investigator 1 Dermavant Sciences, Inc. $2,000.00 10/11/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993568463
Principal investigator 1 Dermavant Sciences, Inc. $2,000.00 10/11/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993568465
Principal investigator 1 Dermavant Sciences, Inc. $1,000.00 10/11/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993568467
Principal investigator 1 Dermavant Sciences, Inc. $1,000.00 10/11/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993568469
Principal investigator 1 Dermavant Sciences, Inc. $1,200.00 10/11/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993568471
Principal investigator 1 Dermavant Sciences, Inc. $1,200.00 10/11/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993568473
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $22,000.00 10/10/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period No dispute reported 06/30/2026 1039783707
Principal investigator 1 Incyte Corporation $32,700.02 10/04/2023 Non-covered Recipient Entity
APEX DERMATOLOGY
A Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus No dispute reported 06/30/2026 1040938363
Principal investigator 1 Janssen Research & Development, LLC $10,944.00 09/15/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 986126935
Principal investigator 1 Amgen Inc. $3,543.12 09/13/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
P3 AD Vaccine Study No dispute reported 06/30/2026 1029655247
Principal investigator 1 Incyte Corporation $5,193.00 09/07/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo No dispute reported 06/30/2026 1040810991
Principal investigator 1 Incyte Corporation $6,313.00 09/07/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo No dispute reported 06/30/2026 1040811003
Principal investigator 1 Dermavant Sciences, Inc. $1,205.06 08/30/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993563611
Principal investigator 1 ABBVIE INC. $4,381.80 08/29/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 998397177
Principal investigator 1 Dermavant Sciences, Inc. $1,611.14 08/26/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993563307
Principal investigator 1 Incyte Corporation $1,935.00 08/17/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1040810955
Principal investigator 1 Incyte Corporation $6,005.00 08/17/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo No dispute reported 06/30/2026 1040810967
Principal investigator 1 Incyte Corporation $1,935.00 08/17/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1040810979
Principal investigator 1 Janssen Research & Development, LLC $2,657.00 08/17/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 986126933
Principal investigator 1 Incyte Corporation $20,635.33 08/10/2023 Non-covered Recipient Entity
APEX DERMATOLOGY
A Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus No dispute reported 06/30/2026 1040938351
Principal investigator 1 Dermavant Sciences, Inc. $2,000.00 08/08/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993562351
Principal investigator 1 Dermavant Sciences, Inc. $1,000.00 08/08/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993562353
Principal investigator 1 Dermavant Sciences, Inc. $1,000.00 08/08/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993562355
Principal investigator 1 Dermavant Sciences, Inc. $1,200.00 08/08/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993562357
Principal investigator 1 Dermavant Sciences, Inc. $1,000.00 08/08/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993562359
Principal investigator 1 Dermavant Sciences, Inc. $21.44 07/28/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993561103
Principal investigator 1 Dermavant Sciences, Inc. $21.44 07/28/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993561105
Principal investigator 1 Dermavant Sciences, Inc. $21.44 07/28/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993561107
Principal investigator 1 Dermavant Sciences, Inc. $21.44 07/28/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993561109
Principal investigator 1 Dermavant Sciences, Inc. $21.44 07/28/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993561111
Principal investigator 1 Dermavant Sciences, Inc. $21.44 07/28/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993561113
Principal investigator 1 Dermavant Sciences, Inc. $87.74 07/28/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993561115
Principal investigator 1 Dermavant Sciences, Inc. $87.74 07/28/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993561117
Principal investigator 1 Dermavant Sciences, Inc. $87.74 07/28/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993561119
Principal investigator 1 Dermavant Sciences, Inc. $87.74 07/28/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993561121
Principal investigator 1 Dermavant Sciences, Inc. $82.34 07/28/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993561123
Principal investigator 1 Dermavant Sciences, Inc. $82.34 07/28/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993561125
Principal investigator 1 Dermavant Sciences, Inc. $82.34 07/28/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993561127
Principal investigator 1 Dermavant Sciences, Inc. $63.42 07/28/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993561129
Principal investigator 1 Dermavant Sciences, Inc. $63.42 07/28/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993561131
Principal investigator 1 Dermavant Sciences, Inc. $63.42 07/28/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993561133
Principal investigator 1 Dermavant Sciences, Inc. $63.42 07/28/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993561135
Principal investigator 1 Dermavant Sciences, Inc. $63.42 07/28/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993561137
Principal investigator 1 Dermavant Sciences, Inc. $63.42 07/28/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993561139
Principal investigator 1 Dermavant Sciences, Inc. $84.80 07/28/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993561141
Principal investigator 1 Dermavant Sciences, Inc. $84.80 07/28/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993561143
Principal investigator 1 Dermavant Sciences, Inc. $84.80 07/28/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993561145
Principal investigator 1 Dermavant Sciences, Inc. $84.80 07/28/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993561147
Principal investigator 1 Dermavant Sciences, Inc. $84.80 07/28/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993561149
Principal investigator 1 Dermavant Sciences, Inc. $84.80 07/28/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993561151
Principal investigator 1 Dermavant Sciences, Inc. $67.98 07/28/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993561153
Principal investigator 1 Incyte Corporation $14,184.00 07/20/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo No dispute reported 06/30/2026 1040810931
Principal investigator 1 Amgen Inc. $11,023.04 07/19/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
P3 AD Adolescent Mono No dispute reported 06/30/2026 1029653443
Principal investigator 1 Janssen Research & Development, LLC $2,862.00 07/14/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 986126931
Principal investigator 1 ABBVIE INC. $1,715.16 07/11/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 998390089
Principal investigator 1 Incyte Corporation $17,478.00 07/06/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo No dispute reported 06/30/2026 1040810919
Principal investigator 1 Incyte Corporation $100.00 07/06/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo No dispute reported 06/30/2026 1040810943
Principal investigator 1 Incyte Corporation $50,975.54 07/06/2023 Non-covered Recipient Entity
APEX DERMATOLOGY
A Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus No dispute reported 06/30/2026 1040938335
Principal investigator 1 Dermavant Sciences, Inc. $1,205.06 06/30/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993559491
Principal investigator 1 Dermavant Sciences, Inc. $1,205.06 06/30/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993559493
Principal investigator 1 Janssen Research & Development, LLC $273.00 06/28/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 986127331
Principal investigator 1 Janssen Research & Development, LLC $6,733.00 06/20/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 986127339
Principal investigator 1 Incyte Corporation $6,650.00 06/15/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1040810907
Principal investigator 1 Dermavant Sciences, Inc. $1,611.14 06/13/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993558923
Recipient Eli Lilly and Company $13,980.00 06/09/2023 Covered Recipient Physician PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED SINGLE-ARM PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB No dispute reported 06/30/2026 1038052463
Principal investigator 1 ABBVIE INC. $1,405.62 06/08/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 998386211
Principal investigator 1 Janssen Research & Development, LLC $6,254.00 06/08/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 986127337
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 06/06/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 986127333
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 06/06/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 986127335
Principal investigator 1 Incyte Corporation $5,065.87 05/26/2023 Non-covered Recipient Entity
APEX DERMATOLOGY
A Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus No dispute reported 06/30/2026 1040938323
Principal investigator 1 Incyte Corporation $20,442.00 05/25/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1040810895
Principal investigator 1 Dermavant Sciences, Inc. $1,205.06 05/20/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993557705
Principal investigator 1 Janssen Research & Development, LLC $5,771.00 05/18/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 986127329
Principal investigator 1 ABBVIE INC. $1,623.08 05/11/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 998382947
Principal investigator 1 ABBVIE INC. $1,608.00 05/11/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 998382959
Principal investigator 1 Dermavant Sciences, Inc. $280.06 05/03/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993556435
Principal investigator 1 Dermavant Sciences, Inc. $1,159.23 05/03/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993556437
Principal investigator 1 Dermavant Sciences, Inc. $1,205.06 05/03/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993556439
Principal investigator 1 Bausch Health US, LLC $6,000.00 05/02/2023 Non-covered Recipient Entity
Apex Clinical Research Center
A PHASE 4 (PHASE 2 IN EUROPEAN UNION), OPEN-LABEL, MULTICENTER STUDY EVALUATING THE ABSORPTION AND SYSTEMIC PHARMACOKINETICS AND HPA AXIS SUPPRESSION POTENTIAL OF TOPICALLY APPLIED IDP-118 LOTION IN PEDIATRIC SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIA No dispute reported 06/30/2026 1055194169
Principal investigator 1 Incyte Corporation $150.00 04/26/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1040810867
Principal investigator 1 Incyte Corporation $29,500.00 04/26/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo No dispute reported 06/30/2026 1040810883
Principal investigator 1 Janssen Research & Development, LLC $3,351.00 04/21/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 986127327
Principal investigator 1 ABBVIE INC. $3,071.28 04/13/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 998378609
Principal investigator 1 ABBVIE INC. $1,405.62 04/13/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 998378611
Principal investigator 1 Dermavant Sciences, Inc. $3,000.00 04/07/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993554381
Principal investigator 1 Dermavant Sciences, Inc. $500.00 04/07/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993554383
Principal investigator 1 Dermavant Sciences, Inc. $1,611.14 04/07/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993554385
Principal investigator 1 Dermavant Sciences, Inc. $1,611.14 04/07/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993554387
Principal investigator 1 Dermavant Sciences, Inc. $1,291.62 04/07/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993554389
Principal investigator 1 Janssen Research & Development, LLC $6,061.00 03/20/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 986127375
Principal investigator 1 Incyte Corporation $24,000.00 03/17/2023 Non-covered Recipient Entity
APEX DERMATOLOGY
A Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus No dispute reported 06/30/2026 1040938311
Principal investigator 1 Incyte Corporation $1,200.00 03/09/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1040810857
Principal investigator 1 Janssen Research & Development, LLC $6,742.00 02/24/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 986127321
Principal investigator 1 Dermavant Sciences, Inc. $407.36 02/17/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993552645
Principal investigator 1 Dermavant Sciences, Inc. $407.36 02/17/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993552647
Principal investigator 1 Dermavant Sciences, Inc. $1,611.14 02/17/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993552649
Principal investigator 1 Dermavant Sciences, Inc. $1,611.14 02/17/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993552651
Principal investigator 1 ABBVIE INC. $2,345.00 02/16/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 No dispute reported 06/30/2026 998371041
Principal investigator 1 ABBVIE INC. $2,872.88 02/09/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 998369515
Principal investigator 1 Janssen Research & Development, LLC $14,250.00 02/01/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 986127323
Principal investigator 1 Janssen Research & Development, LLC $3,391.00 02/01/2023 Non-covered Recipient Entity
Apex Derm
CNTO1959PSO3018 No dispute reported 06/30/2026 986127325
Principal investigator 1 Bausch Health US, LLC $6,000.00 01/31/2023 Non-covered Recipient Entity
Apex Clinical Research Center
A PHASE 4 (PHASE 2 IN EUROPEAN UNION), OPEN-LABEL, MULTICENTER STUDY EVALUATING THE ABSORPTION AND SYSTEMIC PHARMACOKINETICS AND HPA AXIS SUPPRESSION POTENTIAL OF TOPICALLY APPLIED IDP-118 LOTION IN PEDIATRIC SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIA No dispute reported 06/30/2026 1055194167
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $290,072.99 01/26/2023 Non-covered Recipient Entity
Apex Clinical Research
A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUTING IMPACT OF DEUCRAVACITINIB ON QoL, EFFICACY AND SAFETY IN PATIENTS WITH PLAQUE PSORIASIS AND IMPAIRED HEALTH-RELATED QUALITY OF LIFE No dispute reported 06/30/2026 1027484673
Principal investigator 1 PFIZER INC. $2,056.40 01/26/2023 Non-covered Recipient Entity
Apex Clinical Research Center
A PHASE 23 TWOPART STUDY TO EVALUATE THE EFFICACY AND LONGTERM SAFETY WITH ORAL ETRASIMOD 2 MG ONCE DAILY IN ADULT PARTICIPANTS WITH MODERATETOSEVERE ATOPIC DERMATITIS WITH A HISTORY OF PRIOR SYSTEMIC TREATMENT FAILURE No dispute reported 06/30/2026 1046255549
Principal investigator 1 ABBVIE INC. $2,419.96 01/12/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms No dispute reported 06/30/2026 998365753
Principal investigator 1 Dermavant Sciences, Inc. $1,205.06 01/11/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 993550233
Principal investigator 1 Dermavant Sciences, Inc. $407.36 01/11/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993550683
Principal investigator 1 Dermavant Sciences, Inc. $407.36 01/11/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993550685
Principal investigator 1 Dermavant Sciences, Inc. $1,205.06 01/11/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993550687
Principal investigator 1 Dermavant Sciences, Inc. $1,205.06 01/11/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993550689
Principal investigator 1 Dermavant Sciences, Inc. $1,205.06 01/11/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993550691
Principal investigator 1 Dermavant Sciences, Inc. $1,205.06 01/11/2023 Non-covered Recipient Entity
APEX CLINICAL RESEARCH CENTER LLC
A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS No dispute reported 06/30/2026 993550693